Le Lézard
Classified in: Science and technology, Covid-19 virus
Subject: SVY

New Omdia research shows AI processors for the edge will nearly double by 2028

LONDON, Feb. 22, 2024 /PRNewswire/ -- PCs will be the main driver of growth in the AI edge processor market over the next four years, according to new research from Omdia.

This was among the results announced by Omdia in the 2023 edition of its AI Processors for the Edge Forecast, which covers the market for artificial intelligence processors across ten device types including smartphones, PCs, tablets, smart speakers, robots, and UAVs, among others. The total market for AI processors at the edge is expected to grow from $31bn in 2022 to $60bn in 2028, a CAGR of 11%.

Several factors are leading to PCs' growing importance in this market. Product availability is certainly a key factor with Intel's Meteor Lake CPUs recently joining AMD's Ryzen 7040, 8040, and 8000G processors, Apple's M-series, and Qualcomm's Snapdragon Elite X. Also playing a role is the expected rebound of PC market which has slowed recently after a COVID-19 pandemic related surge in 2020 and 2021. Beyond 2025, though, the machines sold during the surge will start approaching the end of their accounting lives, creating the possibility of a refresh cycle that will help with AI PC adoption.

"This is especially important as demand from smartphones ? an early-adopting sector ? is expected to slow" said Alexander Harrowell, Omdia's Principal Analyst for Advanced Computing. "Saturation is certainly a factor in the smartphone market, as over two-thirds of them by volume now have some form of AI acceleration and growth is concentrated in the premium price tier."

The forecast splits the market by processor types such as in-CPU accelerators, AI-ASICs, AI-ASSPs, GPUs, and FPGAs and power/performance bands across the 10 device classes.

As discussed in the report, systems-on-chips introduced in 2018-2019 with basic acceleration are now beginning to drop out of vendors' product lines in favor of more powerful ones. As a result, the lowest and middle performance tiers are emptying out and the next ones up growing, with the strongest growth in the top (>30 TOPS) group. The bulk of growth will come from proprietary AI-ASSPs such as Qualcomm's Snapdragon and Mediatek's APU.

Harrowell added, "AI ASSPs will push from 19% to 28% of the market, largely at the expense of GPUs. PCs are beginning to look more and more like smartphones or tablets as they adopt the CPU-GPU-NPU architecture familiar from nearly all modern smartphones, while in-CPU acceleration has been unexpectedly slow to take off."

Read more in Omdia's AI Processors for Edge Forecast Report ? 2023 Analysis and AI Processors for Edge Forecast Report ? 2023 Database (subscription required).


Omdia, part of Informa Tech, is a technology research and advisory group. Our deep knowledge of tech markets combined with our actionable insights empower organizations to make smart growth decisions.


Fasiha Khan ? [email protected]


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

News published on and distributed by: